A B S T R A C T The effects of tolbutamide and glibenclamide on the metabolism of cyclic AMP were investigated in pancreatic islets of the rat. Changes in cyclic AMP were assessed by measuring 
INTRODUCTION
The mode of action of sulfonylureas, well-known insulin secreting agents (1), is not well understood. However, in recent years evidence has been accumulating suggesting that the adenylate cyclasecyclic AMP' system of the islets is involved in the transmission of the drug effect. In islet homogenates, tolbutamide stimulates adenylate cyclase to a moderate extent (2) and inhibits phosphodiesterase enzyme activity (3) (4) (5) . Recently, Charles and co-workers have reported that tolbutamide increases the cyclic AMP level of perifused islets simultaneously with insulin release (6) .
Insulin secretion induced by sulfonylureas is dependent upon the prevailing glucose concentration. Thus sulfonylurea induces a shift to the left in the glucose dose-response curve for insulin release (1, 7) . The nature of interaction between these drugs and glucose is unknown.
We and others have obtained evidence that glucose increases cyclic AMP concomittantly with insulin secretion, and that this action constitutes an important factor in the regulation of insulin release (8) . Against this background it seemed important to investigate the relationship, if any, between sulfonylurea-and glucose-induced changes in beta-cell cyclic AMP metabolism. To this end, different aspects of a glucosesulfonylurea interaction were investigated: (a), the time-course of sulfonylurea effect in the presence or absence of glucose, (b), the effects of preincubation with glucose on the subsequent sulfonylurea response, and (c), the effects of sulfonylurea over a range of glucose concentrations. In addition, the effects of different conditions inhibiting insulin release on the glucose-and sulfonylurea-induced responses were compared. An indirect method for assessing changes in cyclic AMP metabolism was utilized, namely the conversion of [3H]ATP to [3H]cyclic AMP in prelabeled islets, a procedure whose validity has been confirmed (9) . Two sulfonylureas were chosen: a classical one (tolbutamide), and one representative of the "second generation" of these drugs (glibenclamide). Effects of D-mannoheptulose. To further test the importance of glucose metabolism for sulfonylurea action, the effects of mannoheptulose, an inhibitor of the first step of glycolysis, were tested together with glibenclamide. The concentration of mannoheptulose used completely inhibits the cyclic AMP and insulin responses to 27.7 mM glucose (14) . In the absence of glucose, mannoheptulose had no effect on the glibenclamide-induced 3H cyclic AMP response in 1-and 5-min incubations (Table II) . In the presence of 3.3 mM glucose, however, although the response after 1 min of incubation was unaffected, the glibenclamideinduced rises in [3H]cyclic AMP and insulin release were inhibited by about 50% after 5 min of incubation.
METHODS
Effect of substituting 3.3 mM glucose with Dglyceraldehyde of pyruvate. In 5-min incubations, a low concentration of the glucose metabolite D-glyCeraldehyde (1.5 mM) could at least partly substitute for glucose in prolonging the glibenclamide response, the drug effect on [3H]cyclic AMP being enhanced from 5.1±+ 0.4 to 8.5±+ 1.3 dpm, and insulin release from 0.2±0.1 to 0.4+±0.1 uU (n = 6, P < 0.05 for both parameters, the appropriate control values having been subtracted). Under the same conditions pyruvate (10 mM) was ineffective as a substitute for glucose (results not shown). Effect of preincubation with 27.7 mM glucose. Because the previous experiments had demonstrated that the sulfonylurea effects are profoundly influenced by the presence of even a small, nonstimulatory concentration of glucose, it was investigated whether preincubation with glucose could modify the subsequent response to sulfonylurea. Islets were incubated for 30 min in 27.7 mM, then for 20 min in 3.3 mM glucose, and then exposed to glibenclamide (together with 3.3 mM glucose). As seen in Fig. 3 , the islets which had been preincubated with high glucose responded better to glibenclamide than those exposed to a low glucose concentration, both at an early (1 min) and a later (5 min) time point.
Effect of omission of Ca+'. Omission of Ca++ from the incubation media profoundly depressed the glibenclamide as well as the glucose-induced [3H]-cyclic AMP and insulin responses in 5-min incubations (Fig. 4) .
Effect of epinephrine. tions in incubations of 3 and 30 min' (Fig. 6) . A stimulatory effect of tolbutamide on [3H]cyclic AMP, whether on islet (3 min) or on medium (30 min) levels, was seen at low glucose concentrations (0-6.6 mM). Insulin release was stimulated by the tolbutamide in the absence of glucose; this effect was enhanced by the presence of 3.3 or 6.6 mM glucose (P = <0.05) suggesting potentation by low glucose of the sulfonylurea response. In the presence of a high concentration of glucose (27.7 mM), islet [3H]cyclic AMP was unchanged by tolbutamide whereas the efflux of [3H]-cyclic AMP was actually depressed (Fig. 6 and Table  III) . Insulin release was unaffected by tolbutamide at 27.7 mM glucose (Table I and Fig. 6 ).
Glibenclamide interacted with glucose in a manner similar to that of tolbutamide (Table III) . Glibencla- mide, however, did not inhibit the rise in medium [3H]cyclic AMP evoked by 27.7 mM glucose. Effects of phosphodiesterase inhibition. To investigate whether the sulfonylurea-induced increase in [3H]cyclic AMP is due to phosphodiesterase inhibition, the effect of tolbutamide was tested together with 0-1 mM of the potent phosphodiesterase inhibitor IBMX (Fig. 7) . This substance at 1 mM inhibits the islet enzyme activity almost completely (by 98%);2 it was therefore assumed that if sulfonylurea and IBMX act on the same sites at the phosphodiesterase enzymes, a sulfonylurea effect would diminish with increasing concentrations of IBMX. As seen in Fig. 7 , the tolbutamide effect both on [3H]cyclic AMP and insulin release was, on the contrary, enhanced by increasing concentrations of the phosphodiesterase inhibitor. The effect of glucose (27.7 mM) was magnified in a similar fashion.
DISCUSSION
The present results confirm and extend the observation of Charles and co-workers (6) that sulfonylureas induce a short lasting elevation of the islet cyclic AMP content. Addition of a phosphodiesterase inhibitor in a low concentration in our experiments did not alter the evanescent character of the sulfonylurea action. 2 Unpublished observations. The effects of sulfonylureas on cyclic AMP formation on one hand, and on insulin release on the other, seem to follow each other closely. In the study of Charles et al. (6) , where islet perifusion permitted moment-tomoment correlations, insulin release was parallel to changes in islet cyclic AMP. Also in our batch-type incubations, sulfonylureas induced changes on islet [3H]cyclic AMP and on insulin secretion which were qualitatively similar. Furthermore, the differences in potency and duration between glibenclamide and tolbutamide, that have been well documented regarding insulin secretion (1) , were also found in our system regarding [3H]cyclic AMP formation. All these findings are compatible with the hypothesis that at least part of the secretory effect of sulfonylureas is mediated by their action on the beta-cell adenylate cyclase-cyclic AMP sytem.
To our mind, a most important aspect in the sulfonylurea effect is the interaction that exists between glucose and the drug. Perhaps most striking is the effect of glucose on the timecourse of the sulfonylurea response, where a small, nonstimulatory concentration of glucose (3.3 mM) was sufficient to markedly prolong the stimulating action of glibenclamide on islet [3H]cyclic AMP. Mannoheptulose blocked this time-dependent effect of glucose. These findings are in line with the data of Loubatieres-Mariani and co-workers (15) , who showed that the later but not the immediate insulin response to tolbutamide was inhibited by mannohep-tulose. Another aspect of the glucose dependency for the sulfonylurea effect was revealed in experiments where preincubation with glucose augmented not only the later but also the initial [3H]cyclic AMP response to glibenclamide (Fig. 3) .3 Finally the dosekinetics of glucose-induced cyclic AMP accumulation were subject to modification in the presence of the drug: sulfonylureas shifted the glucose dose-response curve to the left. It should be noted that the inability of sulfonylurea to augment the response to high concentrations of glucose is probably not due to limitations in the maximal capacity of the experimental system since both insulin release and [3H]cyclic AMP accumulation in the presence of 27.7 mM glucose could be further augmented by increasing the concentration of IBMX (Fig. 7) .
What constitutes the basis for the interaction between glucose and sulfonylurea? No definite answers are available, but several possibilities may be raised. It seems probable that the drugs act at the cell membrane because they do not readily penetrate into the cell (16, 17) . One obvious possibility is, then, that sulfonylureas and glucose compete allosterically for a cell membrane receptor, which acts as the signal recognition site that initiates insulin release. The observation that the sulfonylurea but not the glucose effect on cyclic AMP was unaffected by mannoheptulose seems to speak against this explanation. Alternatively, sulfonylureas could facilitate the glucose stimulus for release in an indirect fashion, e.g., by changing ionic fluxes, thus depolarizing the cell membrane (18) , or by modifying the membrane in other ways. We have no direct evidence on this point. Finally, and perhaps additionally to the above-mentioned alternatives, glucose may be necessary as a permissive fuel providing agent for sulfonylurea action. Such a role for glucose is suggested by our observation that preincubation with a high glucose concentration augmented the subsequent response to glibenclamide. It is of interest in this respect that islet ATP (19) and glycogen (20) have been shown to be rapidly depleted after stimulations with sulfonylureas. Howevrer, this should not necessarily indicate that cyclic AMP stimulation, in the absence of glucose, always decreases rapidly because of lack of substrate. Indeed, another adenylate cyclase stimulator, 3 It should be noted that our observations do not exclude the possibility that preincubation with glucose corrects a "starvation" effect on the sensitivity to glibenclamide exerted by the continuous exposure of the islets to a low glucose concentration. The higher responses seen before and then after an added 50-min incubation with 3.3 mM glucose (compare Fig. 2 and left part of Fig. 3 ) may be suggestive of such a time-dependent effect by low glucose. However, the considerable inter-experimental variation encountered with the present in vitro system precludes a quantitative comparison between different sets of experimenits. cholera toxin, stimulates a pronounced and sustained cyclic AMP response in the absence of glucose (21) .
Glucose has been shown to stimulate acutely adenylate cyclase from islet homogenates (22) , whereas sulfonylureas exert small effects both on the adenylate cyclase (2) and phosphodiesterase enzymes (3) (4) (5) . Our results show that, in the intact islet, sulfonylureas do not compete with methylxanthines for inhibition of the phosphodiesterase enzymes (Fig. 7) . We believe therefore that sulfonylureas and glucose increase cyclic AMP by stimulating islet adenylate cyclase(s) rather than by inhibiting the phosphodiesterase activity.
Tolbutamide (but not glibenclamide) inhibited [3H ]-cyclic AMP efflux from the islet. The significance and cause of this observation is unclear. We have recently found that the efflux of cyclic nucleotide from the islet can be modified by agents that affect membrane transport functions (23) . It is possible that tolbutamide, especially with prolonged incubation time, influences cell membrane transport processes; data from erythrocytes appear compatible with this idea (24) . Although the efflux of nucleotide seems to be a sensitive reflection of the time-integrated cyclic AMP stimulation in many experimental systems (25) including islets, (9, 14) , it is obvious that this is not true under all experimental circumstances.
To conclude, our studies suggest that sulfonylureas stimulate insulin release at least partly by stimulating the islet cyclic AMP formation. This effect is strongly modified by the action of glucose. It may therefore be suggested that in vivo the insulinotropic effect of sulfonylureas result from their synergistic action with glucose on the beta-cell adenylate cyclase-cyclic AMP systeni. The molecular basis for this interaction remains to be clarified.
